Anchored in the the ongoing work of the firm's founder at University of Arizona, Veana Therapeutics, Inc. is structured around identifying α-TEA-based cancer immunotherapy technologies. Based on orally bioavailable anti-cancer agents that simultaneously kill tumor cells and stimulate the immune system. α-TEA platform products can be combined with other forms of immunotherapy to further improve anti-tumor activity. The firm's research efforts are producing resslts applicable to a wide variety of cancers. Pre-clinical studies have demonstrated in vitro anti-tumor activity of α-TEA against several disparate cancer cells to include mouse and human triple negative breast, HER2+ breast, melanoma, lung, prostate, and ovarian cancer cells as well as myeloma cell lines. These in vitro studies have been reinforced by in vivo studies in which the anti-tumor activity of orally delivered α-TEA was demonstrated against breast cancer and melanoma. α-TEA stimulates programmed cell death (apoptosis) and "immunogenic cell death" of cancer cells at doses that are not toxic to normal cells. Upon dying, the tumor cells release âdanger signalsâ, which stimulate cells of the immune system to exhibit anti-cancer a
